SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
SpringWorks Therapeutics (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focusing on severe rare diseases and cancer, has announced its plans to report third quarter 2024 financial results on Tuesday, November 12, 2024. The company will host a live conference call and webcast at 8:30 a.m. ET to discuss the financial results and provide recent business updates.
Interested parties can join the live webcast and view the accompanying slides by clicking on the provided link. To participate in the conference call by phone, pre-registration is required through another provided link. Registered participants will receive a dial-in number and conference code for access. A replay of the webcast will be available for a time on the company's Investors & Media section of their website.
SpringWorks Therapeutics (Nasdaq: SWTX), un'azienda biofarmaceutica in fase di commercializzazione che si concentra su malattie rare severe e cancro, ha annunciato i suoi piani per riportare i risultati finanziari del terzo trimestre 2024 martedì 12 novembre 2024. L'azienda ospiterà una conferenza telefonica in diretta e un webcast alle 8:30 a.m. ET per discutere i risultati finanziari e fornire aggiornamenti recenti sull'attività.
Le parti interessate possono partecipare al webcast in diretta e visualizzare le slide correlate cliccando sul link fornito. Per partecipare alla conferenza telefonica, è necessaria la registrazione preventiva tramite un altro link fornito. I partecipanti registrati riceveranno un numero di accesso e un codice conferenza per la partecipazione. Una registrazione del webcast sarà disponibile per un periodo di tempo nella sezione Investitori & Media del sito web dell'azienda.
SpringWorks Therapeutics (Nasdaq: SWTX), una empresa biofarmacéutica en etapa comercial que se enfoca en enfermedades raras severas y cáncer, ha anunciado sus planes para informar sobre los resultados financieros del tercer trimestre de 2024 el martes 12 de noviembre de 2024. La empresa realizará una llamada de conferencia y webcast en vivo a las 8:30 a.m. ET para discutir los resultados financieros y proporcionar actualizaciones recientes sobre el negocio.
Las partes interesadas pueden unirse al webcast en vivo y ver las diapositivas adjuntas haciendo clic en el enlace proporcionado. Para participar en la llamada de conferencia por teléfono, se requiere un registro previo a través de otro enlace proporcionado. Los participantes registrados recibirán un número de acceso y un código de conferencia. Una repetición del webcast estará disponible por un tiempo en la sección de Inversores y Medios de su sitio web.
SpringWorks Therapeutics (Nasdaq: SWTX)는 중증 희귀 질환 및 암에 집중하는 상업 단계의 생명공학 회사로, 2024년 3분기 재무 결과를 2024년 11월 12일 화요일에 발표할 계획이라고 발표했습니다. 회사는 동부 표준시 8:30에 생중계 화상회의 및 웹캐스트를 개최하여 재무 결과를 논의하고 최근 비즈니스 업데이트를 제공합니다.
관심 있는 당사자는 제공된 링크를 클릭하여 생중계 웹캐스트에 참여하고 관련 슬라이드를 볼 수 있습니다. 전화로 회의에 참여하려면 제공된 다른 링크를 통해 사전 등록해야 합니다. 등록된 참가자는 접속을 위한 전화번호와 회의 코드를 받게 됩니다. 웹캐스트의 재생은 회사 웹사이트의 투자자 및 미디어 섹션에서 일정 시간 동안 제공됩니다.
SpringWorks Therapeutics (Nasdaq: SWTX), une entreprise biopharmaceutique en phase commerciale se concentrant sur les maladies rares graves et le cancer, a annoncé ses projets pour publier les résultats financiers du troisième trimestre 2024 le mardi 12 novembre 2024. L'entreprise animera une conférence téléphonique et un webcast en direct à 8h30 ET pour discuter des résultats financiers et donner des mises à jour récentes sur l'activité.
Les parties intéressées peuvent rejoindre le webcast en direct et consulter les diapositives associées en cliquant sur le lien fourni. Pour participer à la conférence téléphonique par téléphone, une préinscription est requise via un autre lien fourni. Les participants inscrits recevront un numéro de connexion et un code de conférence pour y accéder. Un enregistrement du webcast sera disponible pendant un certain temps dans la section Investisseurs & Médias du site web de l'entreprise.
SpringWorks Therapeutics (Nasdaq: SWTX), ein biopharmazeutisches Unternehmen in der Kommerzialisierungsphase, das sich auf schwere seltene Krankheiten und Krebs konzentriert, hat seine Pläne bekannt gegeben, die Finanzergebnisse des dritten Quartals 2024 am Dienstag, den 12. November 2024 zu berichten. Das Unternehmen wird um 8:30 Uhr ET eine Live-Konferenzschaltung und Webcast veranstalten, um die Finanzergebnisse zu diskutieren und aktuelle Geschäftsinformationen bereitzustellen.
Interessierte Parteien können dem Live-Webcast beitreten und die dazugehörigen Folien über den bereitgestellten Link ansehen. Um telefonisch an der Konferenz teilzunehmen, ist eine vorherige Registrierung über einen anderen bereitgestellten Link erforderlich. Registrierte Teilnehmer erhalten eine Einwahlnummer und einen Konferenzcode für den Zugang. Eine Wiederholung des Webcasts wird für eine gewisse Zeit im Bereich Investoren & Media auf der Website des Unternehmens zur Verfügung stehen.
- None.
- None.
STAMFORD, Conn., Oct. 22, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Tuesday, November 12, 2024 to report its third quarter financial results and discuss recent business updates.
To join the live webcast and view the corresponding slides, please click here. To participate in the live conference call by phone, please click here to pre-register. Registered participants will then be provided with a dial-in number and conference code to access the call. A replay of the webcast will be available for a limited time following the event on the Investors & Media section of the Company’s website at https://ir.springworkstx.com.
About SpringWorks Therapeutics
SpringWorks is a commercial-stage biopharmaceutical company applying a precision medicine approach to developing and delivering life-changing medicines for people with severe rare diseases and cancer. OGSIVEO® (nirogacestat), approved in the United States for the treatment of adult patients with progressing desmoid tumors who require systemic treatment, is the Company’s first FDA-approved therapy. SpringWorks also has a diversified targeted therapy pipeline spanning solid tumors and hematological cancers, with programs ranging from preclinical development through advanced clinical trials. In addition to its wholly owned programs, SpringWorks has also entered into multiple collaborations with innovators in industry and academia to unlock the full potential for its portfolio and create more solutions for patients in need.
For more information, visit www.springworkstx.com and follow @SpringWorksTx on X (formerly Twitter), LinkedIn, and YouTube.
Contacts:
Investors
investors@springworkstx.com
Media
media@springworkstx.com
FAQ
When will SpringWorks Therapeutics (SWTX) report its Q3 2024 financial results?
What time is SpringWorks Therapeutics' (SWTX) Q3 2024 earnings call scheduled?
How can investors access SpringWorks Therapeutics' (SWTX) Q3 2024 earnings webcast?
Will there be a replay available for SpringWorks Therapeutics' (SWTX) Q3 2024 earnings call?
